Search 

Abveris is a Massachusetts-based company that provides industry-leading solutions for therapeutic and reagent antibody developements. We have built a strong reputation for our ability to deliver outstanding science. Based on our proprietary hyperimmune mouse models, DiversimAb mouse, and a Beacon-based single B cell screening platform, we have custom-built gene-to-antibody solutions to support development efforts for therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets. Abveris is rapidly expanding its antibody discovery capabilities and geographical presence to work with more emerging biotech to discover therapeutics for novel targets.

Cerevel Therapeutics is a clinical-stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies.

We seek to transform the lives of people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia, through the development of novel therapies. We have built a highly experienced team of senior leaders and neuroscience drug developers who combine a nimble, results-driven biotech mindset with the proven expertise of pharmaceutical company drug discovery and development.

Enosi's lead programs involve novel inhibitors of TNF (tumor necrosis factor), which include severe inflammation associated with viral infections, autoimmune disease, fibrotic diseases, Alzheimer’s, cancer and other diseases. The current TNF inhibitors have important “Black Box” warnings for opportunistic infections, cancer, and cardiovascular events, like stroke. Enosi believes our compounds in development will avoid these limitations of current drugs, be more effective, and will allow expansion into many indications/markets that cannot be approached at the present time by current TNF inhibitors because of their side-effects.

Investment Bank

Nuance Biotech (Shanghai) Co. Ltd was founded in 2014.
Leading China based biotech company focussed on commercial, regulatory and development stage assets.
Nuance is directed by a world class board of directors and managed by an experienced China based management team with a strong track record. Backed a leading global tier 1 investor with more than USD 1 billion under management in China – Matrix Partners. The company strategy and approach allows for a highly scalable commercial and drug development model i.e. ability to run multiple initiatives.

Investment bank focused on Nordic Life Science companies

The Research Institute of Tsinghua University in Shenzhen (RITS) was founded in 1996. RITS strives to establish an innovation incubation system and an industrial investment platform open to both China and abroad, cultivating strategic emerging industries.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.